Optimization of a Series of RIPK2 PROTACs
Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of the inhibitor of apoptosis (IAP) family of E3 ligases. Our PROTAC optimization strategy focused on reducing the lipophilicity of the early lead which resulted in the identification of analogues with improved solubility and increased human and rat microsomal stability. We identified a range of IAP binders that were successfully incorporated into potent RIPK2 PROTACs with attractive pharmacokinetic profiles. Compound 20 possessed the best overall profile with good solubility, potent degradation of RIPK2, and associated inhibition of TNFα release. A proof-of-concept study utilizing a slow release matrix demonstrated the feasibility of a long-acting parenteral formulation with >1 month duration. This represents an attractive alternative dosing paradigm to oral delivery, especially for chronic diseases where compliance can be challenging.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Journal of medicinal chemistry - 64(2021), 17 vom: 09. Sept., Seite 12978-13003 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Miah, Afjal H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.11.1 |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 14.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.jmedchem.1c01118 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329761447 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329761447 | ||
| 003 | DE-627 | ||
| 005 | 20231225205826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.jmedchem.1c01118 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329761447 | ||
| 035 | |a (NLM)34432979 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Miah, Afjal H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimization of a Series of RIPK2 PROTACs |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 14.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Receptor-interacting serine/threonine protein kinase 2 (RIPK2) is an important kinase of the innate immune system. Herein, we describe the optimization of a series of RIPK2 PROTACs which recruit members of the inhibitor of apoptosis (IAP) family of E3 ligases. Our PROTAC optimization strategy focused on reducing the lipophilicity of the early lead which resulted in the identification of analogues with improved solubility and increased human and rat microsomal stability. We identified a range of IAP binders that were successfully incorporated into potent RIPK2 PROTACs with attractive pharmacokinetic profiles. Compound 20 possessed the best overall profile with good solubility, potent degradation of RIPK2, and associated inhibition of TNFα release. A proof-of-concept study utilizing a slow release matrix demonstrated the feasibility of a long-acting parenteral formulation with >1 month duration. This represents an attractive alternative dosing paradigm to oral delivery, especially for chronic diseases where compliance can be challenging | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a RIPK2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Receptor-Interacting Protein Serine-Threonine Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Smith, Ian E D |e verfasserin |4 aut | |
| 700 | 1 | |a Rackham, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Mares, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Thawani, Aditya R |e verfasserin |4 aut | |
| 700 | 1 | |a Nagilla, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Haile, Pamela A |e verfasserin |4 aut | |
| 700 | 1 | |a Votta, Bartholomew J |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Laurie J |e verfasserin |4 aut | |
| 700 | 1 | |a Watt, Gillian |e verfasserin |4 aut | |
| 700 | 1 | |a Denyer, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Don T |e verfasserin |4 aut | |
| 700 | 1 | |a Dace, Phoebe |e verfasserin |4 aut | |
| 700 | 1 | |a Giffen, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Goncalves, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Churcher, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Scott-Stevens, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Harling, John D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medicinal chemistry |d 1963 |g 64(2021), 17 vom: 09. Sept., Seite 12978-13003 |w (DE-627)NLM000006602 |x 1520-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2021 |g number:17 |g day:09 |g month:09 |g pages:12978-13003 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.jmedchem.1c01118 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2021 |e 17 |b 09 |c 09 |h 12978-13003 | ||